Share this:
Mayo breast cancer study provides critical information on tumor sequencing and response to chemotherapy
Article by Colette Gallagher, Public Affairs
Mayo Clinic researchers reported in the Journal of the National Cancer Institute the results of the Breast Cancer Genome-Guided Therapy (BEAUTY) study designed to help researchers and physicians better understand why current standard chemotherapy stops breast cancer in some women but fails in others.
Tumor sequencing is increasingly used to select treatment for patients with cancer, but its role in women with newly diagnosed breast cancer is unknown. Mayo Clinic researchers looked at the feasibility of obtaining cancer tumor genome sequencing data and creating patient-derived mouse avatars in the chemotherapy before surgery setting.
This data provides an invaluable tool for drug development and targeted therapy, especially in chemotherapy resistant tumors.
Dr. Matthew Goetz
“There is great interest to use tumor sequencing data to guide therapy,” says Matthew Goetz, M.D., medical oncologist and co-chair of the BEAUTY study. “However, there are limited data as to whether this approach is useful in women with newly diagnosed breast cancer who are recommended chemotherapy prior to breast surgery,” he added.
Learn more about precision medicine and join our community
Get the latest news from the Center for Individualized Medicine. Visit our blog, Facebook, LinkedIn or Twitter at @MayoClinicCIM.
Save the date for the 2017 Individualizing Medicine Conference on Oct. 9-11. Registration opens Monday, April 3. For a complete schedule and list of speakers, visit the conference website.
Tags: #Breast Cancer Genome-Guided Therapy study, #DNA sequencing tests, #Journal of the National Cancer Institute, #tumor sequencing, breast cancer, center for individualized medicine, chemotherapy, Dr. Judy Boughey, Dr. Matthew Goetz, mayo clinic, Mayo Clinic Cancer Center, medical research, Precision Medicine